Riccardo Dolcetti

37 Kent Str
Woolloongabba, QLD 4102, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma.

Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 29, 2026

Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells.

Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells.

Journal: Clinical & translational immunology

Published: September 24, 2025

Cryptic but critical: non-canonical antigens in cancer immunotherapy.

Cryptic but critical: non-canonical antigens in cancer immunotherapy.

Journal: Trends in immunology

Published: June 03, 2025

Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.

Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.

Journal: Cancers

Published: May 16, 2025

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene

Published: March 03, 2025

Reduced HLA-I Transcript Levels and Increased Abundance of a CD56dim NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas.

Reduced HLA-I Transcript Levels and Increased Abundance of a CD56dim NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas.

Journal: Cancers

Published: February 26, 2025

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?

Journal: Journal of experimental & clinical cancer research : CR

Published: November 24, 2024

Transcriptional signature of CD56bright NK cells predicts favourable prognosis in bladder cancer.

Transcriptional signature of CD56bright NK cells predicts favourable prognosis in bladder cancer.

Journal: Frontiers in immunology

Published: August 02, 2024

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene

Published: February 14, 2024

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Journal: Frontiers in immunology

Published: November 10, 2023

Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.

Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.

Journal: Cancer research

Published: July 10, 2023

Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell-based vaccine efficiency to elicit antitumor immune response in vitro.

Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell-based vaccine efficiency to elicit antitumor immune response in vitro.

Journal: Cytotherapy

Published: June 22, 2023

Showing 1-12 of 122

Last Updated: 09/26/2026